TD Cowen raised the firm’s price target on GeneDx (WGS) to $118 from $75 and keeps a Buy rating on the shares. The firm reviewed its financial model following the stock’s rise and believes there is room for upside noting its published trial studies support its strong competitive position.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS: